News

Mauna Kea Technologies announces results of its Combined General Meeting of June 5, 2025 

5 June 2025

All the resolutions proposed by the Board of Directors were adopted 

Paris and Boston, June 5, 2025 – 5:45 p.m. CEST – Mauna Kea Technologies (Euronext Growth: ALMKT), inventor of Cellvizio®, the multidisciplinary probe and needle-based confocal laser endomicroscopy (p/nCLE) platform, held its Combined General Meeting of June 5, 2025, which was chaired by Mr. Sacha Loiseau, Chairman of the Board of Directors and CEO. 

With a quorum of 38.5%, all the resolutions proposed by the Board of Directors have been adopted. Among the main resolutions approved were the adoption of the annual and consolidated financial statements for the year ended December 31, 2024, the allocation of the 2024 net result, as well as delegations granted to the Board of Directors related to financial transactions. 

Details on the vote results are available on the Company’s website

READ THE COMPLETE PRESS RELEASE

Latest News

Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 

Mauna Kea Technologies Announces Major AI Breakthrough with Cellvizio in Pancreatic Cystic Lesion Risk Stratification 

Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 

Mauna Kea Technologies Provides Update on Safeguard Proceedings, Strategic Discussions and Operational Progress 

Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

Mauna Kea Technologies announces the availability of preparatory documents for the Combined General Meeting of June 5, 2025 and the instructions for participation 

No results found.